Onco Wiki / Maladie

Thrombocythémie essentielle

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-ET
TypeMaladie
Alias
ETThrombocythémie essentiellethrombocythémie primaireЕсенціальна тромбоцитемія
Étatreviewed 2026-04-25 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-ESMO-MPN-2015 SRC-NCCN-MPN-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology9962/3
icd_o_3_topography["C42.1"]
icd_10D47.3
who_classificationEssential thrombocythaemia (ET) — Ph-negative myeloproliferative neoplasm (per WHO 5th ed.)

Capacités

Notes

Authored as separate disease from PV (see DIS-PV.notes for rationale). Treatment: low-risk ET → ASA only (avoid in extreme thrombocytosis with acquired vWD); high-risk → HU 1L; anagrelide 2L (PT-1 trial — non-inferior on thrombosis but more arterial events + bleeding + MF progression). PreT-PMF ("prefibrotic primary myelofibrosis") is increasingly distinguished from ET on trephine — has worse prognosis and behaves more like PMF; current scope: standard ET only. STUB — requires clinical co-lead signoff before publication. Myeloid expansion (heme).

Utilisé par

Pertinence thérapeutique

Algorithmes

Maladie

Indication

Questionnaires

Signal d’alerte

Sources